{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:55:48Z","timestamp":1791183348178,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10637-012-9818-6","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T05:20:22Z","timestamp":1335763222000},"page":"2391-2399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Daniel","family":"Laheru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. V.","family":"Rajeshkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Goldsweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Donehower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongweon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"9818_CR1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"9818_CR2","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"9818_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605\u20131617","journal-title":"N Engl J Med"},{"key":"9818_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825","journal-title":"N Engl J Med"},{"key":"9818_CR5","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801\u20131806","journal-title":"Science"},{"key":"9818_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ccr.2007.01.012","volume":"11","author":"C Guerra","year":"2007","unstructured":"Guerra C, Schuhmacher AJ, Canamero M, Schuhmacher AJ, Hern\u00e1ndez-Porras I, Ca\u00f1amero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291\u2013302","journal-title":"Cancer Cell"},{"key":"9818_CR7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","volume":"22","author":"E Van Cutsem","year":"2004","unstructured":"Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430\u20131438","journal-title":"J Clin Oncol"},{"key":"9818_CR8","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","volume":"17","author":"EK Rowinsky","year":"1999","unstructured":"Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17:3631\u20133652","journal-title":"J Clin Oncol"},{"key":"9818_CR9","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","volume":"18","author":"B Weisz","year":"1999","unstructured":"Weisz B, Giehl K, Gana-Weisz M, Ben-Baruch G, Marciano D, Gierschik P et al (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579\u20132588","journal-title":"Oncogene"},{"key":"9818_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-007-0451-6","volume":"61","author":"R Haklai","year":"2008","unstructured":"Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y (2008) Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61:89\u201396","journal-title":"Cancer Chemother Pharmacol"},{"key":"9818_CR11","first-page":"555","volume":"8","author":"M Gana-Weisz","year":"2002","unstructured":"Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y (2002) The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8:555\u2013565","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9818_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00280-009-1027-4","volume":"65","author":"A Tsimberidou","year":"2010","unstructured":"Tsimberidou A, Rudek MA, Hong D, Ng CS, Blair J, Goldsweih H et al (2010) Phase I first-i-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol 65(2):235\u2013241","journal-title":"Cancer Chemother Pharmacol"},{"key":"9818_CR13","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-06-0113","volume":"12","author":"B Rubio-Viqueira","year":"2006","unstructured":"Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652\u20134661","journal-title":"Clin Cancer Res"},{"key":"9818_CR14","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","volume":"17","author":"NV Rajeshkumar","year":"2011","unstructured":"Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T et al (2011) MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17:2799\u20132806","journal-title":"Clin Cancer Res"},{"key":"9818_CR15","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-08-3021","volume":"15","author":"NV Rajeshkumar","year":"2009","unstructured":"Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S et al (2009) Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 15:4138\u20134146","journal-title":"Clin Cancer Res"},{"key":"9818_CR16","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1158\/1535-7163.MCT-10-0370","volume":"9","author":"NV Rajeshkumar","year":"2010","unstructured":"Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, L\u00f3pez-R\u00edos F, Fujiwara K, Matsui WH et al (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 9:2582\u20132592","journal-title":"Mol Cancer Ther"},{"key":"9818_CR17","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1200\/JCO.2008.16.2347","volume":"26","author":"A Jimeno","year":"2008","unstructured":"Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A et al (2008) Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26:4172\u20134179","journal-title":"J Clin Oncol"},{"key":"9818_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jchromb.2008.05.028","volume":"869","author":"M Zhao","year":"2008","unstructured":"Zhao M, He P, Xu L, Hidalgo M, Laheru D, Rudek MA (2008) Determination of salirasib (S-trans, trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 869:142\u2013145","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"9818_CR19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York, pp 409\u2013417"},{"key":"9818_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc2960","volume":"10","author":"D Vigil","year":"2010","unstructured":"Vigil D, Cherfils J, Rossman KL, Der CJ (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10:842\u2013857","journal-title":"Nat Rev Cancer"},{"key":"9818_CR21","doi-asserted-by":"crossref","unstructured":"Von Hoff DD, Ramanathan RK, Borad M, Laheru D, Smith LS, Wood TE, et al (2011) Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. Oct 3. [Epub ahead of print]","DOI":"10.1200\/JCO.2011.36.5742"},{"key":"9818_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjc.6605819","volume":"103","author":"I Garrido-Laguna","year":"2010","unstructured":"Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC et al (2010) Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103:649\u2013655","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9818-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9818-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9818-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9818-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:38:47Z","timestamp":1678559927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9818-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["9818"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9818-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]},"assertion":[{"value":"20 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}